Parmax Pharma Limited
PARMAX.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$520.41M
Close$
$-88.98
164% downside
Current Fair Value
164% downsideOvervalued by 164% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $520.41 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.12 |
| Beta | 0.59 |
| Outstanding Shares | 3,740,634 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -43.47 |
|---|---|
| PEG | 11.21 |
| Price to Sales | 2.84 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Parmax Pharma Limited
9 employees
CEO: Umang Alkesh Gosalia Parmax Pharma Limited primarily manufactures active pharmaceutical ingredients (APIs), including ampicillin, amoxicillin, cephalexin, and nalidixic acid. The company also intends to expand its activities into the formulation of finished ...